Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.

Abhishek A Solanki^1,2, William Adams³, James A Proudfoot⁴, Kristin Baldea^2,5, Güliz A Barkan^2,6, Alec M Block^1,2, Neil B Desai⁷, Ahmer Farooq^2,5, Michael R Folkert⁸, Aurelie Garant⁷, Alex Gorbonos^2,5, Gopal Gupta^2,5, Hyejoo Kang^1,2, Eileen Kelly⁴, Steven Kregel⁹, Stanley L Liauw¹⁰, Christopher K Luminais¹¹, Michael Mysz², Marcus L Quek^2,5, Timothy N Showalter¹¹, James S Welsh¹, Michael Woods^2,5, Elai Davicioni⁴, William Small^1,2, Matthew M Harkenrider^1,2

¹Department of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.

²Loyola University Medical Center, Maywood, IL.

³Department of Medicine, Loyola University Chicago, Maywood, IL.

⁴Veracyte, Inc, San Diego, CA.

⁵Department of Urology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.

⁶Department of Pathology and Laboratory Medicine, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.

⁷Department of Radiation Oncology, University of Texas Southwestern, Dallas, TX.

⁸Department of Radiation Oncology, University of Washington, Seattle, WA.

⁹Department of Cancer Biology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.

¹⁰Department of Radiation and Cellular Oncology, Pritzker School of Medicine, University of Chicago, Chicago, IL.

¹¹Department of Radiation Oncology, University of Virginia, Charlottesville, VA.

PubMed DOI

Abstract

PURPOSE: Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. METHODS…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.